Breathe Well Live Well
|
Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen
FierceBiotech Genentech, though, appears to be out front with its new antibody–which Amgen had dubbed AMG 282–now headed into Phase II for asthma and COPD as investigators set out to see if they can control the diseases by shutting down the IL-33 pathway. |
View full post on asthma – Google News
|
Amgen, AstraZeneca prep a brodalumab pitch–after scuttling asthma program
FierceBiotech Amgen and its partner AstraZeneca are winding up to deliver U.S. and European applications for their big blockbuster hopeful brodalumab for plaque psoriasis by mid-year. But their last shot to push ahead with the drug in asthma ran into defeat, with … |
View full post on asthma – Google News
|
Amgen Posts Positive Phase I Results For Asthma Drug
BioResearch Online (press release) Amgen reported positive results from the Phase I study showing that inhibiting thymic stromal lymphopoietin (TSLP) could be useful in the treatment of asthma. TSLP is a cytokine considered to be a key driver of the allergic inflammation that … Anti-thymic stromal lymphopoietin therapy reduced allergy-induced … |
View full post on asthma – Google News
Drug Discovery & Development |
Amgen Publishes Asthma Drug Proof-of-Concept in NEJM
Drug Discovery & Development Amgen announced that The New England Journal of Medicine (NEJM) published positive results from a Phase 1 study adding to the growing body of evidence that inhibiting thymic stromal lymphopoietin (TSLP) could be beneficial in the treatment of asthma. Novel Antibody Demonstrates Promise against Asthma Amgen drug for allergy asthma shows promise in early tests Novel Biologic Promising for Allergic Asthma |
View full post on asthma – Google News
|
Amgen drug for allergy asthma shows promise in early tests
SFGate An experimental compound from Amgen Inc. succeeded in blunting allergic asthma attacks by blocking a protein newly found to cause symptoms, researchers said. The drug, called AMG 157, focuses on a signaling protein known as thymic stromal … Novel Biologic Promising for Allergic Asthma New antibody can improve quality of life for individuals with asthma New Amgen drug shows early promise for managing allergic asthma attacks |
View full post on asthma – Google News
|
Reports from Amgen Provide New Insights into Asthma
4-traders (press release) According to news reporting out of Thousand Oaks, California , by NewsRx editors, research stated, "IL-17 signaling has been implicated in development and persistence of asthma. Cytokine-targeted strategies blocking IL-17 receptor signaling may be … |
View full post on asthma – Google News
 Telegraph.co.uk |
MedImmune parent, Amgen launch partnership
Gazette.Net: Maryland Community News Online AstraZeneca is to lead the development and commercial strategy of three candidates, AMG 139, AMG 157 and AMG 181, which are being studied to treat Crohn's disease, asthma and ulcerative colitis, respectively. Amgen will spearhead efforts regarding … Amgen and AstraZeneca Announce Collaboration to Jointly Develop and … Big Pharma Buys Access To This Promising Biotech Pipeline AstraZeneca, Amgen enter into development and commercialization agreement |
View full post on asthma – Google News